Back to discover
Disease

Cicatrix

Late-stage therapeutic developmentEmerging research
MeSHCicatrix
6
Publications
10
Clinical trials
1
Related conditions
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Clinical trials

3 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
10
All trials
0
Active
2
Late-stage
6
Completed
Recently completed

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars

Phase 2 · Completed · Maternal and Child Health Hospital of Foshan

A Double Blind, Within Patient, Placebo Controlled Trial to Assess the Efficacy of Juvista (Avotermin) in Conjunction With Scar Revision Surgery for the Improvement of Disfiguring Scars.

Phase 3 · Completed · Renovo

A Double-Blind, Placebo-Controlled, Randomised Dose Ranging Trial to Investigate the Efficacy of Two Different Dosing Regimens of Avotermin (Juvista) in the Improvement of Scar Appearance When Applied to Approximated Wound Margins in Healthy Volunteers.

Phase 2 · Completed · Renovo

A Double-Blind, Placebo-Controlled, Randomised Dose-Ranging Trial to Investigate the Efficacy of Avotermin (Juvista) in the Improvement of Scar Appearance When Applied to Approximated Wound Margins in Healthy Volunteers

Phase 2 · Completed · Renovo

A Single-centre, Placebo- and Standard-care-controlled, Double-blind, Randomised Trial to Investigate the Efficacy of Eight Doses of RN1003 in the Reduction of Scarring From the Approximated Wound Margins of Incisional Wounds

Phase 2 · Completed · Renovo

A Single-site, Placebo-controlled, Double-blind Trial to Investigate the Safety, Tolerability, Systemic Exposure and the Scar-improvement Efficacy of Intradermal Applications of Three Doses of Juvidex (5.64mg/100μl, 2.82mg/100μl and 11.28mg/100μl) Given Once Only or Three Times Within and Between Male and Female Subjects Aged 18-45.

Phase 2 · Completed · Renovo

Research activity

6 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20062023
Major themes8
  • Cicatrix2
  • Wound Healing2
  • Biocompatible Materials1
  • Exosomes1
  • Immune System1
  • Immunomodulation1
  • Mesenchymal Stem Cells1
  • Pancreatic Neoplasms1
Leading journals6
  • Advances in wound care1
  • International endodontic journal1
  • International journal of nanomedicine1
  • Nature communications1
  • Signal transduction and targeted therapy1
  • The oncologist1
Leading researchers8
  • Bhardwaj N1
  • Chen KT1
  • Chu C1
  • Cui R1
  • Darwish O1
  • Ebot E1
  • Fabrizio D1
  • Fleischmann Z1
Affiliations (unnormalised)6
  • Brigham and Women's Hospital and Harvard Medical School1
  • California Northstate University College of Medicine1
  • Department of Oral Implantology & State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases1
  • Department of Prosthodontics & State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases1
  • Foundation Medicine1
  • Institute of Oral Biology1

Related conditions

1 match

Diseases frequently studied alongside this one. Number shows shared papers.

Inflammation2

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Cicatrix is fibrous tissue that forms in place of normal tissue during wound healing. It represents the scar left after tissue repair and can be discussed in the context of normal healing or pathological scar formation.

Causes

Cicatrix forms as a consequence of wound healing after tissue injury. The supplied material also links scar formation to over-repair and excessive tissue proliferation in skin injury, but does not support a broader aetiology beyond healing after damage.

Pathophysiology

The underlying process is wound healing, in which injured tissue is replaced by fibrous tissue. In pathological scar formation, excessive repair and tissue proliferation are associated with inflammatory and immunomodulatory processes, leading to scar attenuation or scarring rather than restoration of normal tissue architecture.

Risk factors

Tissue injury and disruption of normal wound healing are the main factors implied by the grounding. The literature also associates chronic inflammation and dysfunctional inflammatory pathways with chronic wounds and scar formation, but no specific patient-level risk factors are supported here.

Current standard of care

Management is described at the modality level as therapies that modulate wound healing and reduce scarring. The supplied reviews mention immunomodulatory approaches such as mesenchymal stem cell-derived exosomes, mechanical force application, and bioscaffolds, but do not establish a single standard treatment for cicatrix itself.

AI-generated summary grounded in MeSH and 4 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

The fibrous tissue that replaces normal tissue during the process of WOUND HEALING.

Identifiers
MeSHCicatrix
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.